Moderna Shares Slump As Citi Downgrades To 'Sell’ After Cancer Vaccine Rally
Moderna's stock price rose sharply over several months after the company announced positive results from a late-stage trial of a melanoma vaccine. Following this rally, the financial firm Citigroup downgraded Moderna's stock rating to "sell," suggesting the price had risen too far relative to the company's prospects.
← Back to stories
National3 articles from 3 sources across the spectrum· Updated 7d ago
3 across the spectrum · tap a section to jump
How each side is putting it
Left
1 viewpointCenter
1 viewpointRight
1 viewpointAfter Moderna's Dizzying Rally, It's Time To Sell, Says Analyst